{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:11:54Z","timestamp":1791159114207,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.jconrel.2013.01.011","type":"journal-article","created":{"date-parts":[[2013,1,23]],"date-time":"2013-01-23T16:36:54Z","timestamp":1358959014000},"page":"189-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"title":["Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension"],"prefix":"10.1016","volume":"167","author":[{"given":"Vivek","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imam H.","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Mehvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan F.","family":"McMurtry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Nozik-Grayck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fakhrul","family":"Ahsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2013.01.011_bb0005","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ccm.2011.02.015","article-title":"Alternatives to lung transplantation: treatment of pulmonary arterial hypertension","volume":"32","author":"Corris","year":"2011","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0010","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12325-011-0005-5","article-title":"Prostacyclins in pulmonary arterial hypertension: the need for earlier therapy","volume":"28","author":"Vachiery","year":"2011","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0015","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/HYPERTENSIONAHA.110.157032","article-title":"Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension","volume":"57","author":"Chen","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.jconrel.2013.01.011_bb0020","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1161\/HYPERTENSIONAHA.108.121418","article-title":"Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension","volume":"53","author":"Kimura","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.jconrel.2013.01.011_bb0025","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/jps.21946","article-title":"Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension","volume":"99","author":"Gupta","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0030","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/med.20140","article-title":"Nanoparticle formulations in pulmonary drug delivery","volume":"29","author":"Bailey","year":"2009","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0035","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/thx.47.4.257","article-title":"Liposomes for controlled delivery of drugs to the lung","volume":"47","author":"Taylor","year":"1992","journal-title":"Thorax"},{"key":"10.1016\/j.jconrel.2013.01.011_bb0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0168-3659(03)00359-6","article-title":"Agglomerated vesicle technology: a new class of particles for controlled and modulated pulmonary drug delivery","volume":"93","author":"Bhavane","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.01.011_bb0045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1023\/A:1020178304031","article-title":"Biophysical aspects of using liposomes as delivery vehicles","volume":"22","author":"Ulrich","year":"2002","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0050","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1128\/AAC.31.5.675","article-title":"Liposomes as carriers of antimicrobial agents","volume":"31","author":"Lopez-Berestein","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0055","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijpharm.2008.01.046","article-title":"Inhalable liposomal formulation for vasoactive intestinal peptide","volume":"357","author":"Hajos","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0060","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/PL00022055","article-title":"Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: formulation aspects and stability","volume":"24","author":"Kleemann","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0065","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bbamem.2006.11.017","article-title":"Association of vasoactive intestinal peptide with polymer-grafted liposomes: structural aspects for pulmonary delivery","volume":"1768","author":"Stark","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2013.01.011_bb0070","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/bjp.2008.239","article-title":"Therapeutic potential of RhoA\/Rho kinase inhibitors in pulmonary hypertension","volume":"155","author":"Oka","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0075","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2005.06.003","article-title":"Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial","volume":"238","author":"Shibuya","year":"2005","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0080","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejpb.2004.06.009","article-title":"Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation","volume":"59","author":"Zhang","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0085","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jconrel.2012.07.003","article-title":"PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin","volume":"162","author":"Patel","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.01.011_bb0090","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1002\/jps.22160","article-title":"Inhalable liposomes of low molecular weight heparin for the treatment of venous thromboembolism","volume":"99","author":"Bai","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0095","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0378-5173(01)00896-1","article-title":"Encapsulation of an antivasospastic drug, fasudil, into liposomes, and in vitro stability of the fasudil-loaded liposomes","volume":"232","author":"Ishida","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0100","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s11095-011-0409-6","article-title":"PLGA microparticles encapsulating prostaglandin E1-hydroxypropyl-beta-cyclodextrin (PGE1-HPbetaCD) complex for the treatment of pulmonary arterial hypertension (PAH)","volume":"28","author":"Gupta","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0105","doi-asserted-by":"crossref","first-page":"L885","DOI":"10.1152\/ajplung.00258.2006","article-title":"Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling","volume":"292","author":"Crossno","year":"2007","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/02652049509010292","article-title":"Factors affecting microencapsulation of drugs in liposomes","volume":"12","author":"Kulkarni","year":"1995","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0115","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-1-60327-360-2_9","article-title":"Remote loading of anthracyclines into liposomes","volume":"605","author":"Lewrick","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0120","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0005-2736(86)90105-7","article-title":"Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient","volume":"857","author":"Mayer","year":"1986","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2013.01.011_bb0125","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/08982104.2010.545070","article-title":"Development of stealth liposome coencapsulating doxorubicin and fluoxetine","volume":"21","author":"Ong","year":"2011","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0130","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/jps.22017","article-title":"A mathematical relationship for hydromorphone loading into liposomes with trans-membrane ammonium sulfate gradients","volume":"99","author":"Tu","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0005-2736(93)90105-9","article-title":"Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases","volume":"1151","author":"Haran","year":"1993","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2013.01.011_bb0140","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0014-5793(96)00452-8","article-title":"Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time","volume":"386","author":"Uster","year":"1996","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0145","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbamem.2003.11.016","article-title":"pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol","volume":"1661","author":"Dos Santos","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2013.01.011_bb0150","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S0006-3495(93)81383-3","article-title":"Mechanical properties of vesicles. I. Coordinated analysis of osmotic swelling and lysis","volume":"64","author":"Ertel","year":"1993","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0155","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2217\/nnm.10.100","article-title":"Efficient gene delivery by EGF-lipoplexes in vitro and in vivo","volume":"6","author":"Bunuales","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2013.01.011_bb0160","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0006-3495(86)83741-9","article-title":"Transmission electron microscopy observations of sonication-induced changes in liposome structure","volume":"49","author":"Zasadzinski","year":"1986","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0165","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1248\/bpb.29.397","article-title":"Safe and efficient drug delivery system with liposomes for intrathecal application of an antivasospastic drug, fasudil","volume":"29","author":"Ishida","year":"2006","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0170","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0009-3084(93)90062-8","article-title":"The use of differential scanning calorimetry as a tool to characterize liposome preparations","volume":"64","author":"Biltonen","year":"1993","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.jconrel.2013.01.011_bb0175","first-page":"111","article-title":"Factors affecting drug release from liposomes","volume":"13","author":"Lindner","year":"2010","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0180","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1211\/jpp.59.1.0010","article-title":"Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification","volume":"59","author":"Chono","year":"2007","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0185","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1161\/hc1002.105938","article-title":"Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina","volume":"105","author":"Masumoto","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2013.01.011_bb0190","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0008-6363(99)00144-3","article-title":"Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm","volume":"43","author":"Shimokawa","year":"1999","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0195","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s11095-008-9562-y","article-title":"Role of particle size in phagocytosis of polymeric microspheres","volume":"25","author":"Champion","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0200","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0927-7765(02)00042-5","article-title":"Phagocytic uptake of polystyrene microspheres by alveolar macrophages: effects of the size and surface properties of the microspheres","volume":"27","author":"Makino","year":"2003","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.jconrel.2013.01.011_bb0205","first-page":"957","article-title":"Susceptibility of exogenous surfactant to phospholipase A2 degradation","volume":"74","author":"Duncan","year":"1996","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0210","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/ajrccm.150.4.7921463","article-title":"In vivo function of surfactants containing phosphatidylcholine analogs","volume":"150","author":"Dizon-Co","year":"1994","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0215","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1203\/00006450-198507000-00019","article-title":"Pulmonary toxicity of monocrotaline differs at critical periods of lung development","volume":"19","author":"Todd","year":"1985","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0220","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1164\/ajrccm.157.5.9709050","article-title":"Pulmonary artery remodeling differs in hypoxia- and monocrotaline-induced pulmonary hypertension","volume":"157","author":"van Suylen","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0225","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/hrt.2003.029470","article-title":"Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension","volume":"91","author":"Fukumoto","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.jconrel.2013.01.011_bb0230","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1164\/rccm.200405-637OC","article-title":"Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension","volume":"171","author":"Nagaoka","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0235","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/FJC.0b013e31802df112","article-title":"Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats","volume":"49","author":"Jiang","year":"2007","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0240","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.addr.2007.05.015","article-title":"Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development","volume":"59","author":"Mahmood","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2013.01.011_bb0245","series-title":"Guidance for Industry: Estimating the Maximum safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers","first-page":"1","year":"2005"},{"key":"10.1016\/j.jconrel.2013.01.011_bb0250","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00380-009-1176-8","article-title":"Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension","volume":"25","author":"Fujita","year":"2010","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jconrel.2013.01.011_bb0255","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v27.i4.20","article-title":"Inhalational therapy for pulmonary arterial hypertension: current status and future prospects","volume":"27","author":"Gupta","year":"2010","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591300028X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591300028X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:28:20Z","timestamp":1759159700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836591300028X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S016836591300028X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2013.01.011","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2013.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}